NEOFORDEX
Live / Registered — International registration cancelled — extension of protection cancelled (as of 01 Feb 2024)
What this means for you
Registered since 24 Mar 2015. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79144403
- Registration number
- 4705767
- Mark type
- Stylized text
- Filed
- 31 Jan 2014
- Published for opposition
- 06 Jan 2015
- Registered
- 24 Mar 2015
- Attorney of record
- M. Scott Alprin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary products for treating progression of chronic diseases, proliferative diseases, and for treating rheumatological diseases; pharmaceutical and veterinary products for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; pharmaceutical and veterinary products for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; pharmaceutical and veterinary products for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura; pills, capsules, tablets, and powders pertaining to healthy diet for use in treating oncological diseases; chemical preparations for medical and pharmaceutical use for treating progression of chronic diseases, proliferative disease, and for treating rheumatological diseases; chemical preparations for medical and pharmaceutical use for treating oncological diseases, especially colon cancer, rectum cancer, breast cancer, prostate cancer, pancreatic cancer, gastric cancer, thyroid cancer, larynx cancer, liver cancer, uterine cancer, cervical cancer, esophagus cancer, ovarian cancer, lung cancer, pleural cancer, oral cavity cancer, kidney cancer, bladder cancer, testicular cancer, melanoma, lymphatic cancer, hematopoietic cancer, carcinoma, sarcoma, nervous system cancer, particularly primary tumors; chemical preparations for medical and pharmaceutical use for treating onco-haematological diseases, especially lymphomas, especially Hodgkin's disease and non-Hodgkin lymphomas, lymphadenopathy, myeloma, especially multiple myeloma, and leukemia; chemical preparations for medical and pharmaceutical use for treating haematological diseases, especially amyloses, and purpura, especially thrombocytopenic purpura
Owner
- THERAVIA, FR
- LABORATOIRES C.T.R.S., FR
- LABORATOIRES C.T.R.S., FR
Prosecution history
- 17 Aug 2024 — NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
- 17 Aug 2024 — DEATH OF INTERNATIONAL REGISTRATION
- 12 Feb 2024 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 02 Oct 2022 — TOTAL INVALIDATION PROCESSED BY THE IB
- 07 Sept 2022 — TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
- 07 Sept 2022 — INVALIDATION PROCESSED
- 26 Jul 2022 — TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
- 26 Nov 2021 — CANCELLED SECTION 71
- 07 May 2020 — NEW REPRESENTATIVE AT IB RECEIVED
- 24 Mar 2020 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 15 Nov 2019 — NEW REPRESENTATIVE AT IB RECEIVED
- 18 Sept 2015 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 30 Jul 2015 — FINAL DISPOSITION NOTICE SENT TO IB
- 30 Jul 2015 — FINAL DISPOSITION PROCESSED
- 24 Jun 2015 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB